<DOC>
	<DOCNO>NCT01479465</DOCNO>
	<brief_summary>This randomize study compare efficacy simtuzumab ( GS-6624 ) versus placebo combination FOLFIRI ( fluorouracil , leucovorin , irinotecan ) chemotherapy regimen participant metastatic KRAS mutant colorectal cancer .</brief_summary>
	<brief_title>Efficacy Safety Simtuzumab With FOLFIRI Second Line Treatment Colorectal Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>Metastatic Colorectal Carcinoma KRAS mutation . Received first line therapy discontinue part first line therapy . Estimated life expectancy &gt; 3 month . Stage IV disease . Eastern Cooperative Oncology Group ( ECOG ) 02 . Adequate hepatic hematologic function No major operation within 4 week prior treatment start . More 1 prior chemotherapy regimen stage 4 colorectal cancer . Experimental medical treatment within 30 day prior study entry . Known suspected cerebral metastasis . History presence form cancer , colorectal cancer , within 3 year prior enrollment . Known dihydropyrimidine dehydrogenasedeficiency ( special screening require ) . Subjects angina pectoris , poorly control ventricular arrhythmia ( include asymptomatic , occasional premature ventricular contraction ) , history clinically significant coronary heart disease cardiomyopathy , ECG abnormalities consistent ischemia . Uncontrolled hypertension ( seat systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 110 mmHg ) Screening . Clinically active liver disease , include active hepatitis ( etiology ) cirrhosis . Antitumor therapy ( chemotherapy , antibody therapy , molecular target therapy , retinoid therapy , hormonal therapy ) within 21 day prior randomization Prior irinotecan therapy metastatic disease permit . Systemic fungal , bacterial , viral , infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>GSI</keyword>
	<keyword>Gilead</keyword>
	<keyword>Gilead Sciences</keyword>
	<keyword>GS-6624</keyword>
	<keyword>Colorectal Cancer</keyword>
	<keyword>KRAS</keyword>
	<keyword>Oncology</keyword>
	<keyword>monoclonal antibody</keyword>
</DOC>